Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR)

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $35.00 price target on Kymera Therapeutics (NASDAQ: KYMR).

The analyst commented: "Positive Pipeline expansion with novel IRF5 targeting degrader; STAT6 HV data on track for June; We are incrementally positive on KYMR following today's 1Q25 business update showcasing KT-579, an oral, selective degrader of IRF5 protein that plays a key role across multiple I&I disease states (RA, IBD, SLE) as indicated by biology, GWAS studies, and preclinical models. While still early in development, we see potential for complementarity to existing I&I programs. KYMR has also discontinued KT-295 (TYK2 degrader; no value in our model) to focus primarily on STAT6 (in our view) and advance IRF5 development, extending cash runway to 1H28 from mid-2027, as per mgmt. KT-621 remains near-term focus (recent deepdive HERE) and we remain buyers into HV data in June."

For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.

Shares of Kymera Therapeutics closed at $30.07 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Dover Corp. (DOV) PT Raised to $230 at Morgan Stanley
• Arm Holdings (ARM) PT Raised to $500 at Mizuho